Mesenchymal tumours of the pleura: review and update.
immunohistochemistry
mesenchymal
molecular
pleura
sarcoma
spindle
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
10
08
2023
received:
26
06
2023
accepted:
14
08
2023
pubmed:
11
9
2023
medline:
11
9
2023
entrez:
11
9
2023
Statut:
ppublish
Résumé
Primary mesenchymal tumours of the pleura are uncommon and can be diagnostically challenging due to their overlapping histopathologic and immunophenotypic features. Herein we discuss selected mesenchymal tumours of the pleura, including solitary fibrous tumour, calcifying fibrous tumour, desmoid fibromatosis, synovial sarcoma, schwannoma, malignant peripheral nerve sheath tumour, inflammatory myofibroblastic tumour, follicular dendritic cell sarcoma, epithelioid hemangioendothelioma, and desmoplastic small round cell tumour. We review their clinicopathologic characteristics, along with an update on the relevant immunohistochemical and molecular features.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
163-182Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Said JW, Nash G, Banks-Schlegel S, Sassoon AF, Shintaku IP. Localized fibrous mesothelioma: an immunohistochemical and electron microscopic study. Hum. Pathol. 1984; 15; 440-443.
el-Naggar AK, Ro JY, Ayala AG et al. Localized fibrous tumor of the serosal cavities. Immunohistochemical, electron-microscopic, and flow-cytometric DNA study. Am. J. Clin. Pathol. 1989; 92; 561-565.
England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am. J. Surg. Pathol. 1989; 13; 640-658.
Briselli M, Mark EJ, Dickersin GR. Solitary fibrous tumors of the pleura: eight new cases and review of 360 cases in the literature. Cancer 1981; 47; 2678-2689.
de Perrot M, Kurt AM, Robert JH, Borisch B, Spiliopoulos A. Clinical behavior of solitary fibrous tumors of the pleura. Ann. Thorac. Surg. 1999; 67; 1456-1459.
Yousem SA, Flynn SD. Intrapulmonary localized fibrous tumor. Intraparenchymal so-called localized fibrous mesothelioma. Am. J. Clin. Pathol. 1988; 89; 365-369.
Witkin GB, Rosai J. Solitary fibrous tumor of the mediastinum. A report of 14 cases. Am. J. Surg. Pathol. 1989; 13; 547-557.
Hanau CA, Miettinen M. Solitary fibrous tumor: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites. Hum. Pathol. 1995; 26; 440-449.
Yamada Y, Kohashi K, Kinoshita I et al. Clinicopathological review of solitary fibrous tumors: dedifferentiation is a major cause of patient death. Virchows Arch. 2019; 475; 467-477.
Demicco EG, Park MS, Araujo DM et al. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod. Pathol. 2012; 25; 1298-1306.
Tapias LF, Mercier O, Ghigna MR et al. Validation of a scoring system to predict recurrence of resected solitary fibrous tumors of the pleura. Chest 2015; 147; 216-223.
Demicco EG, Wagner MJ, Maki RG et al. Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. Mod. Pathol. 2017; 30; 1433-1442.
Salas S, Resseguier N, Blay JY et al. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. Ann. Oncol. 2017; 28; 1979-1987.
Reisenauer JS, Mneimneh W, Jenkins S et al. Comparison of risk stratification models to predict recurrence and survival in pleuropulmonary solitary fibrous tumor. J. Thorac. Oncol. 2018; 13; 1349-1362.
van de Rijn M, Lombard CM, Rouse RV. Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum, and lung. Am. J. Surg. Pathol. 1994; 18; 814-820.
Flint A, Weiss SW. CD-34 and keratin expression distinguishes solitary fibrous tumor (fibrous mesothelioma) of pleura from desmoplastic mesothelioma. Hum. Pathol. 1995; 26; 428-431.
Chilosi M, Facchettti F, Dei Tos AP et al. Bcl-2 expression in pleural and extrapleural solitary fibrous tumours. J. Pathol. 1997; 181; 362-367.
Ng TL, Gown AM, Barry TS et al. Nuclear beta-catenin in mesenchymal tumors. Mod. Pathol. 2005; 18; 68-74.
Schirosi L, Lantuejoul S, Cavazza A et al. Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR. Am. J. Surg. Pathol. 2008; 32; 1627-1642.
Schweizer L, Koelsche C, Sahm F et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013; 125; 651-658.
Doyle LA, Vivero M, Fletcher CD et al. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod. Pathol. 2014; 27; 390-395.
Doyle LA, Tao D, Marino-Enriquez A. STAT6 is amplified in a subset of dedifferentiated liposarcoma. Mod. Pathol. 2014; 27; 1231-1237.
Papke DJ Jr, Dickson BC, Oliveira AM et al. Distinctive nested glomoid neoplasm: clinicopathologic analysis of 20 cases of a mesenchymal neoplasm with frequent GLI1 alterations and indolent behavior. Am. J. Surg. Pathol. 2023; 47; 12-24.
Chmielecki J, Crago AM, Rosenberg M et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat. Genet. 2013; 45; 131-132.
Robinson DR, Wu YM, Kalyana-Sundaram S et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat. Genet. 2013; 45; 180-185.
Barthelmess S, Geddert H, Boltze C et al. Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features. Am. J. Pathol. 2014; 184; 1209-1218.
Akaike K, Kurisaki-Arakawa A, Hara K et al. Distinct clinicopathological features of NAB2-STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential. Hum. Pathol. 2015; 46; 347-356.
Tai HC, Chuang IC, Chen TC et al. NAB2-STAT6 fusion types account for clinicopathological variations in solitary fibrous tumors. Mod. Pathol. 2015; 28; 1324-1335.
Huang SC, Li CF, Kao YC et al. The clinicopathological significance of NAB2-STAT6 gene fusions in 52 cases of intrathoracic solitary fibrous tumors. Cancer Med. 2016; 5; 159-168.
Bahrami A, Lee S, Schaefer IM et al. TERT promoter mutations and prognosis in solitary fibrous tumor. Mod. Pathol. 2016; 29; 1511-1522.
Demicco EG, Wani K, Ingram D et al. TERT promoter mutations in solitary fibrous tumour. Histopathology 2018; 73; 843-851.
Lin Y, Seger N, Tsagkozis P et al. Telomerase promoter mutations and copy number alterations in solitary fibrous tumours. J. Clin. Pathol. 2018; 71; 832-839.
Mosquera JM, Fletcher CD. Expanding the spectrum of malignant progression in solitary fibrous tumors: a study of 8 cases with a discrete anaplastic component-is this dedifferentiated SFT? Am. J. Surg. Pathol. 2009; 33; 1314-1321.
Dagrada GP, Spagnuolo RD, Mauro V et al. Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation. Mod. Pathol. 2015; 28; 1074-1083.
Yamada Y, Kohashi K, Kinoshita I et al. Histological background of dedifferentiated solitary fibrous tumour. J. Clin. Pathol. 2022; 75; 397-403.
Thway K, Hayes A, Ieremia E, Fisher C. Heterologous osteosarcomatous and rhabdomyosarcomatous elements in dedifferentiated solitary fibrous tumor: further support for the concept of dedifferentiation in solitary fibrous tumor. Ann. Diagn. Pathol. 2013; 17; 457-463.
Collini P, Negri T, Barisella M et al. High-grade sarcomatous overgrowth in solitary fibrous tumors: a clinicopathologic study of 10 cases. Am. J. Surg. Pathol. 2012; 36; 1202-1215.
Pinkard NB, Wilson RW, Lawless N et al. Calcifying fibrous pseudotumor of pleura. A report of three cases of a newly described entity involving the pleura. Am. J. Clin. Pathol. 1996; 105; 189-194.
Jang KS, Oh YH, Han HX et al. Calcifying fibrous pseudotumor of the pleura. Ann. Thorac. Surg. 2004; 78; e87-e88.
Zamecnik M, Boudova L, Sulc M, Michal M. Location of calcifying fibrous pseudotumour: peritoneal predominance. Histopathology 2005; 46; 346.
Kawahara K, Yasukawa M, Nakagawa K, Katsura H, Nagano T, Iwasaki T. Multiple calcifying fibrous tumor of the pleura. Virchows Arch. 2005; 447; 1007-1008.
Suh JH, Shin OR, Kim YH. Multiple calcifying fibrous pseudotumor of the pleura. J. Thorac. Oncol. 2008; 3; 1356-1358.
Isaka M, Nakagawa K, Maniwa T et al. Disseminated calcifying tumor of the pleura: review of the literature and a case report with immunohistochemical study of its histogenesis. Gen. Thorac. Cardiovasc. Surg. 2011; 59; 579-582.
Fetsch JF, Montgomery EA, Meis JM. Calcifying fibrous pseudotumor. Am. J. Surg. Pathol. 1993; 17; 502-508.
Kocova L, Michal M, Sulc M et al. Calcifying fibrous pseudotumour of visceral peritoneum. Histopathology 1997; 31; 182-184.
Pomplun S, Goldstraw P, Davies SE, Burke MM, Nicholson AG. Calcifying fibrous pseudotumour arising within an inflammatory pseudotumour: evidence of progression from one lesion to the other? Histopathology 2000; 37; 380-382.
Hill KA, Gonzalez-Crussi F, Chou PM. Calcifying fibrous pseudotumor versus inflammatory myofibroblastic tumor: a histological and immunohistochemical comparison. Mod. Pathol. 2001; 14; 784-790.
Sigel JE, Smith TA, Reith JD, Goldblum JR. Immunohistochemical analysis of anaplastic lymphoma kinase expression in deep soft tissue calcifying fibrous pseudotumor: evidence of a late sclerosing stage of inflammatory myofibroblastic tumor? Ann. Diagn. Pathol. 2001; 5; 10-14.
Nascimento AF, Ruiz R, Hornick JL, Fletcher CDM. Calcifying fibrous ‘pseudotumor’: clinicopathologic study of 15 cases and analysis of its relationship to inflammatory myofibroblastic tumor. Int. J. Surg. Pathol. 2002; 10; 189-196.
Peachell M, Mayo J, Kalloger S, Flint J, English J. Calcifying fibrous pseudotumour of the lung. Thorax 2003; 58; 1018-1019.
Chang JW, Kim JH, Maeng YH. Calcifying fibrous pseudotumor of the anterior mediastinum. Korean J. Thorac. Cardiovasc. Surg. 2011; 44; 318-320.
Rudez I, Legac A, Baric D, Manojlović S, Unic D, Sutlic Z. Asymptomatic calcifying fibrous pseudotumor compressing heart cavities. Ann. Thorac. Surg. 2011; 91; 291-293.
Van Dorpe J, Ectors N, Geboes K et al. Is calcifying fibrous pseudotumor a late sclerosing stage of inflammatory myofibroblastic tumor? Am. J. Surg. Pathol. 1999; 23; 329-335.
Tomassen T, Koelsche C, de Leng WWJ et al. Calcifying fibrous tumor and inflammatory myofibroblastic tumor are epigenetically related: a comparative genome-wide methylation study. Ann. Diagn. Pathol. 2019; 41; 102-105.
Mehrad M, LaFramboise WA, Lyons MA et al. Whole-exome sequencing identifies unique mutations and copy number losses in calcifying fibrous tumor of the pleura: report of 3 cases and review of the literature. Hum. Pathol. 2018; 78; 36-43.
Wilson RW, Gallateau-Salle F, Moran CA. Desmoid tumors of the pleura: a clinicopathologic mimic of localized fibrous tumor. Mod. Pathol. 1999; 12; 9-14.
Takeshima Y, Nakayori F, Nakano T et al. Extra-abdominal desmoid tumor presenting as an intrathoracic tumor: case report and literature review. Pathol. Int. 2001; 51; 824-828.
Meyerson SL, D'Amico TA. Intrathoracic desmoid tumor: brief report and review of literature. J. Thorac. Oncol. 2008; 3; 656-659.
Burke AP, Sobin LH, Shekitka KM, Federspiel BH, Helwig EB. Intra-abdominal fibromatosis. A pathologic analysis of 130 tumors with comparison of clinical subgroups. Am. J. Surg. Pathol. 1990; 14; 335-341.
Colombo C, Foo WC, Whiting D et al. FAP-related desmoid tumors: a series of 44 patients evaluated in a cancer referral center. Histol. Histopathol. 2012; 27; 641-649.
Crago AM, Denton B, Salas S et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann. Surg. 2013; 258; 347-353.
Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C et al. Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am. J. Surg. Pathol. 2005; 29; 653-659.
Bekers EM, van Broekhoven DLM, van Dalen T et al. Multifocal occurrence of extra-abdominal desmoid type fibromatosis-a rare manifestation. A clinicopathological study of 6 sporadic cases and 1 hereditary case. Ann. Diagn. Pathol. 2018; 35; 38-41.
Zreik RT, Fritchie KJ. Morphologic spectrum of desmoid-type fibromatosis. Am. J. Clin. Pathol. 2016; 145; 332-340.
Colombo C, Bolshakov S, Hajibashi S et al. 'Difficult to diagnose' desmoid tumours: a potential role for CTNNB1 mutational analysis. Histopathology 2011; 59; 336-340.
Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am. J. Pathol. 1997; 151; 329-334.
Saito T, Oda Y, Tanaka K et al. Beta-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours. J. Pathol. 2001; 195; 222-228.
Dai Y, Bedrossian CW, Michael CW. The expression pattern of beta-catenin in mesothelial proliferative lesions and its diagnostic utilities. Diagn. Cytopathol. 2005; 33; 320-324.
Rakheja D, Molberg KH, Roberts CA et al. Immunohistochemical expression of beta-catenin in solitary fibrous tumors. Arch. Pathol. Lab. Med. 2005; 129; 776-779.
Andino L, Cagle PT, Murer B et al. Pleuropulmonary desmoid tumors: immunohistochemical comparison with solitary fibrous tumors and assessment of beta-catenin and cyclin D1 expression. Arch. Pathol. Lab. Med. 2006; 130; 1503-1509.
Amary MF, Pauwels P, Meulemans E et al. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool. Am. J. Surg. Pathol. 2007; 31; 1299-1309.
Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 2007; 51; 509-514.
Barak S, Wang Z, Miettinen M. Immunoreactivity for calretinin and keratins in desmoid fibromatosis and other myofibroblastic tumors: a diagnostic pitfall. Am. J. Surg. Pathol. 2012; 36; 1404-1409.
Zhou L, Xu H, Zhou J et al. Nuclear TFE3 expression is a diagnostic marker for Desmoid-type fibromatosis. Diagn. Pathol. 2019; 14; 34.
Scott RJ, Froggatt NJ, Trembath RC, Evans DG, Hodgson SV, Maher ER. Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3′ APC gene mutation. Hum. Mol. Genet. 1996; 5; 1921-1924.
Li C, Bapat B, Alman BA. Adenomatous polyposis coli gene mutation alters proliferation through its beta-catenin-regulatory function in aggressive fibromatosis (desmoid tumor). Am. J. Pathol. 1998; 153; 709-714.
Lazar AJ, Tuvin D, Hajibashi S et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am. J. Pathol. 2008; 173; 1518-1527.
Salas S, Chibon F, Noguchi T et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer 2010; 49; 560-568.
Le Guellec S, Soubeyran I, Rochaix P et al. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Mod. Pathol. 2012; 25; 1551-1558.
Mullen JT, DeLaney TF, Rosenberg AE et al. Beta-catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist 2013; 18; 1043-1049.
Huss S, Nehles J, Binot E et al. Beta-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis. Histopathology 2013; 62; 294-304.
Crago AM, Chmielecki J, Rosenberg M et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer 2015; 54; 606-615.
van Broekhoven DL, Verhoef C, Grunhagen DJ et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann. Surg. Oncol. 2015; 22; 1464-1470.
Kasper B, Gruenwald V, Reichardt P, Bauer S, Hohenberger P, Haller F. Correlation of CTNNB1 mutation status with progression arrest rate in RECIST progressive desmoid-type fibromatosis treated with imatinib: translational research results from a phase 2 study of the German Interdisciplinary Sarcoma Group (GISG-01). Ann. Surg. Oncol. 2016; 23; 1924-1927.
Koike H, Nishida Y, Kohno K et al. Is immunohistochemical staining for beta-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study. Hum. Pathol. 2019; 84; 155-163.
Gaertner E, Zeren EH, Fleming MV et al. Biphasic synovial sarcomas arising in the pleural cavity. A clinicopathologic study of five cases. Am. J. Surg. Pathol. 1996; 20; 36-45.
Nicholson AG, Goldstraw P, Fisher C. Synovial sarcoma of the pleura and its differentiation from other primary pleural tumours: a clinicopathological and immunohistochemical review of three cases. Histopathology 1998; 33; 508-513.
Aubry MC, Bridge JA, Wickert R, Tazelaar HD. Primary monophasic synovial sarcoma of the pleura: five cases confirmed by the presence of SYT-SSX fusion transcript. Am. J. Surg. Pathol. 2001; 25; 776-781.
Essary LR, Vargas SO, Fletcher CD. Primary pleuropulmonary synovial sarcoma: reappraisal of a recently described anatomic subset. Cancer 2002; 94; 459-469.
Begueret H, Galateau-Salle F, Guillou L et al. Primary intrathoracic synovial sarcoma: a clinicopathologic study of 40 t(X;18)-positive cases from the French Sarcoma Group and the Mesopath Group. Am. J. Surg. Pathol. 2005; 29; 339-346.
Cummings NM, Desai S, Thway K et al. Cystic primary pulmonary synovial sarcoma presenting as recurrent pneumothorax: report of 4 cases. Am. J. Surg. Pathol. 2010; 34; 1176-1179.
Tajima S, Takahashi T, Itaya T, Koda K, Neyatani H. Cystic synovial sarcoma of the pleura mimicking a cystic thymoma: a case report illustrating the role of decreased INI-1 expression in differential diagnosis. Int. J. Clin. Exp. Pathol. 2015; 8; 3262-3269.
Lan T, Chen H, Xiong B et al. Primary pleuropulmonary and mediastinal synovial sarcoma: a clinicopathologic and molecular study of 26 genetically confirmed cases in the largest institution of southwest China. Diagn. Pathol. 2016; 11; 62.
Rossi G, Farnedi A, Davoli F et al. An unexpected cause of recurrent pneumothorax. Pathologica 2022; 114; 316-321.
Erber R, Haller F, Hartmann A, Agaimy A. Prominent entrapment of respiratory epithelium in primary and metastatic intrapulmonary non-epithelial neoplasms: a frequent morphological pattern closely mimicking adenofibroma and other biphasic pulmonary lesions. Virchows Arch. 2020; 477; 195-205.
Kang Y, Pekmezci M, Folpe AL, Ersen A, Horvai AE. Diagnostic utility of SOX10 to distinguish malignant peripheral nerve sheath tumor from synovial sarcoma, including intraneural synovial sarcoma. Mod. Pathol. 2014; 27; 55-61.
Terry J, Saito T, Subramanian S et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am. J. Surg. Pathol. 2007; 31; 240-246.
Lino-Silva LS, Flores-Gutierrez JP, Vilches-Cisneros N et al. TLE1 is expressed in the majority of primary pleuropulmonary synovial sarcomas. Virchows Arch. 2011; 459; 615-621.
Klebe S, Prabhakaran S, Hocking A et al. Pleural malignant mesothelioma versus pleuropulmonary synovial sarcoma: a clinicopathological study of 22 cases with molecular analysis and survival data. Pathology 2018; 50; 629-634.
Miettinen M, Limon J, Niezabitowski A, Lasota J. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am. J. Surg. Pathol. 2001; 25; 610-617.
Matsuyama A, Hisaoka M, Iwasaki M, Iwashita M, Hisanaga S, Hashimoto H. TLE1 expression in malignant mesothelioma. Virchows Arch. 2010; 457; 577-583.
Zaborowski M, Vargas AC, Pulvers J et al. When used together SS18-SSX fusion-specific and SSX C-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases. Histopathology 2020; 77; 588-600.
Baranov E, McBride MJ, Bellizzi AM et al. A novel SS18-SSX fusion-specific antibody for the diagnosis of synovial sarcoma. Am. J. Surg. Pathol. 2020; 44; 922-933.
Perret R, Velasco V, Le Guellec S et al. The SS18-SSX antibody has perfect specificity for the SS18-SSX fusion protein: a validation study of 609 neoplasms including 2 unclassified tumors with SS18-non-SSX fusions. Am. J. Surg. Pathol. 2021; 45; 582-584.
Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N. Engl. J. Med. 1998; 338; 153-160.
Storlazzi CT, Mertens F, Mandahl N et al. A novel fusion gene, SS18L1/SSX1, in synovial sarcoma. Genes Chromosomes Cancer 2003; 37; 195-200.
Argani P, Zhang L, Sung YS et al. Novel SS18-NEDD4 gene fusion in a primary renal synovial sarcoma. Genes Chromosomes Cancer 2020; 59; 203-208.
Yoshida A, Arai Y, Satomi K et al. Identification of novel SSX1 fusions in synovial sarcoma. Mod. Pathol. 2022; 35; 228-239.
Guillou L, Benhattar J, Bonichon F et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J. Clin. Oncol. 2004; 22; 4040-4050.
Jacoby LB, MacCollin M, Barone R, Ramesh V, Gusella JF. Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosomes Cancer 1996; 17; 45-55.
Kehrer-Sawatzki H, Farschtschi S, Mautner VF, Cooper DN. The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. Hum. Genet. 2017; 136; 129-148.
Hu S, Chen Y, Wang Y, Chen KM, Song Q. Clinical and CT manifestation of pleural schwannoma. Acta Radiol. 2012; 53; 1137-1141.
Boland JM, Colby TV, Folpe AL. Intrathoracic peripheral nerve sheath tumors-a clinicopathological study of 75 cases. Hum. Pathol. 2015; 46; 419-425.
Gray MH, Rosenberg AE, Dickersin GR et al. Glial fibrillary acidic protein and keratin expression by benign and malignant nerve sheath tumors. Hum. Pathol. 1989; 20; 1089-1096.
Fanburg-Smith JC, Majidi M, Miettinen M. Keratin expression in schwannoma; A study of 115 retroperitoneal and 22 peripheral schwannomas. Mod. Pathol. 2006; 19; 115-121.
Oh JE, Ohta T, Satomi K et al. Alterations in the NF2/LATS1/LATS2/YAP pathway in schwannomas. J. Neuropathol. Exp. Neurol. 2015; 74; 952-959.
Agnihotri S, Jalali S, Wilson MR et al. The genomic landscape of schwannoma. Nat. Genet. 2016; 48; 1339-1348.
Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57; 2006-2021.
Le Guellec S, Decouvelaere AV, Filleron T et al. Malignant peripheral nerve sheath tumor is a challenging diagnosis: a systematic pathology review, immunohistochemistry, and molecular analysis in 160 patients from the French Sarcoma Group Database. Am. J. Surg. Pathol. 2016; 40; 896-908.
Berner EA, Hung YP, Nielsen GP, Lozano-Calderón SA. Malignant peripheral nerve sheath tumors arising from schwannomas: case series and literature review. APMIS 2021; 129; 524-532.
Ordonez NG, Tornos C. Malignant peripheral nerve sheath tumor of the pleura with epithelial and rhabdomyoblastic differentiation: report of a case clinically simulating mesothelioma. Am. J. Surg. Pathol. 1997; 21; 1515-1521.
Pekmezci M, Reuss DE, Hirbe AC et al. Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Mod. Pathol. 2015; 28; 187-200.
Schaefer IM, Fletcher CD, Hornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod. Pathol. 2016; 29; 4-13.
Prieto-Granada CN, Wiesner T, Messina JL, Jungbluth AA, Chi P, Antonescu CR. Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST. Am. J. Surg. Pathol. 2016; 40; 479-489.
Cleven AH, Sannaa GA, Briaire-de Bruijn I et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod. Pathol. 2016; 29; 582-590.
Asano N, Yoshida A, Ichikawa H et al. Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumours. Histopathology 2017; 70; 385-393.
Mito JK, Qian X, Doyle LA, Hornick JL, Jo VY. Role of histone H3K27 trimethylation loss as a marker for malignant peripheral nerve sheath tumor in fine-needle aspiration and small biopsy specimens. Am. J. Clin. Pathol. 2017; 148; 179-189.
Makise N, Sekimizu M, Konishi E et al. H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features. Mod. Pathol. 2019; 32; 435-445.
Yamada Y, Kinoshita I, Miyazaki Y et al. Myxoid type and non-myxoid type of intimal sarcoma in large vessels and heart: review of histological and genetic profiles of 20 cases. Virchows Arch. 2022; 480; 919-925.
Bottillo I, Ahlquist T, Brekke H et al. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J. Pathol. 2009; 217; 693-701.
Zhang M, Wang Y, Jones S et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat. Genet. 2014; 46; 1170-1172.
Lee W, Teckie S, Wiesner T et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat. Genet. 2014; 46; 1227-1232.
Jo VY, Fletcher CD. Epithelioid malignant peripheral nerve sheath tumor: clinicopathologic analysis of 63 cases. Am. J. Surg. Pathol. 2015; 39; 673-682.
Carter JM, O'Hara C, Dundas G et al. Epithelioid malignant peripheral nerve sheath tumor arising in a schwannoma, in a patient with “neuroblastoma-like” schwannomatosis and a novel germline SMARCB1 mutation. Am. J. Surg. Pathol. 2012; 36; 154-160.
Rekhi B, Kosemehmetoglu K, Tezel GG, Dervisoglu S. Clinicopathologic features and immunohistochemical spectrum of 11 cases of epithelioid malignant peripheral nerve sheath tumors, including INI1/SMARCB1 results and BRAF V600E analysis. APMIS 2017; 125; 679-689.
Schaefer IM, Dong F, Garcia EP, Fletcher CDM, Jo VY. Recurrent SMARCB1 inactivation in epithelioid malignant peripheral nerve sheath tumors. Am. J. Surg. Pathol. 2019; 43; 835-843.
Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am. J. Surg. Pathol. 1995; 19; 859-872.
Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am. J. Surg. Pathol. 2007; 31; 509-520.
Dongel I, Yazkan R, Duman L et al. Huge inflammatory myofibroblastic tumor of pleura with concomitant nuchal fibroma. Ann. Thorac. Surg. 2013; 96; 1461-1464.
Yamamoto H, Yamaguchi H, Aishima S et al. Inflammatory myofibroblastic tumor versus IgG4-related sclerosing disease and inflammatory pseudotumor: a comparative clinicopathologic study. Am. J. Surg. Pathol. 2009; 33; 1330-1340.
Taylor MS, Chougule A, MacLeay AR et al. Morphologic overlap between inflammatory myofibroblastic tumor and IgG4-related disease: lessons from next-generation sequencing. Am. J. Surg. Pathol. 2019; 43; 314-324.
Lovly CM, Gupta A, Lipson D et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov. 2014; 4; 889-895.
Yamamoto H, Yoshida A, Taguchi K et al. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. Histopathology 2016; 69; 72-83.
Chang JC, Zhang L, Drilon AE et al. Expanding the molecular characterization of thoracic inflammatory myofibroblastic tumors beyond ALK gene rearrangements. J. Thorac. Oncol. 2019; 14; 825-834.
Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KSJ, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod. Pathol. 2001; 14; 569-576.
Chan JK, Cheuk W, Shimizu M. Anaplastic lymphoma kinase expression in inflammatory pseudotumors. Am. J. Surg. Pathol. 2001; 25; 761-768.
Cook JR, Dehner LP, Collins MH et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am. J. Surg. Pathol. 2001; 25; 1364-1371.
Cessna MH, Zhou H, Sanger WG et al. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod. Pathol. 2002; 15; 931-938.
Antonescu CR, Suurmeijer AJ, Zhang L et al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am. J. Surg. Pathol. 2015; 39; 957-967.
Hornick JL, Sholl LM, Dal Cin P, Childress MA, Lovly CM. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. Mod. Pathol. 2015; 28; 732-739.
Yamamoto H, Nozaki Y, Kohashi K, Kinoshita I, Oda Y. Diagnostic utility of pan-Trk immunohistochemistry for inflammatory myofibroblastic tumours. Histopathology 2020; 76; 774-778.
Mason EF, Fletcher CD, Sholl LM. ‘Inflammatory myofibroblastic tumour’-like dedifferentiation of anaplastic lymphoma kinase-rearranged lung adenocarcinoma. Histopathology 2016; 69; 510-515.
Cheah AL, Zou Y, Lanigan C et al. ALK expression in angiomatoid fibrous histiocytoma: a potential diagnostic pitfall. Am. J. Surg. Pathol. 2019; 43; 93-101.
Walters M, Pittelkow MR, Hasserjian RP et al. Follicular dendritic cell sarcoma with indolent T-lymphoblastic proliferation is associated with paraneoplastic autoimmune multiorgan syndrome. Am. J. Surg. Pathol. 2018; 42; 1647-1652.
Alqaidy D, Moran CA. Primary follicular dendritic cell sarcoma of the pleura: a clinicopathological and immunohistochemical study of two cases. Ann. Diagn. Pathol. 2022; 58; 151944.
Viola P, Vroobel KM, Devaraj A et al. Follicular dendritic cell tumour/sarcoma: a commonly misdiagnosed tumour in the thorax. Histopathology 2016; 69; 752-761.
Perez-Ordonez B, Erlandson RA, Rosai J. Follicular dendritic cell tumor: report of 13 additional cases of a distinctive entity. Am. J. Surg. Pathol. 1996; 20; 944-955.
Lorenzi L, Doring C, Rausch T et al. Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing. Oncotarget 2017; 8; 16463-16472.
Tao LL, Huang YH, Chen YL, Yu GY, Yin WH. SSTR2a is a useful diagnostic marker for follicular dendritic cells and their related tumors. Am. J. Surg. Pathol. 2019; 43; 374-381.
Wu YL, Wu F, Xu CP et al. Mediastinal follicular dendritic cell sarcoma: a rare, potentially under-recognized, and often misdiagnosed disease. Diagn. Pathol. 2019; 14; 5.
Ohgami RS, Zhao S, Ohgami JK et al. TdT+ T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma. Am. J. Surg. Pathol. 2012; 36; 1619-1628.
Griffin GK, Sholl LM, Lindeman NI, Fletcher CDM, Hornick JL. Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF-kappaB regulatory genes. Mod. Pathol. 2016; 29; 67-74.
Andersen EF, Paxton CN, O'Malley DP et al. Genomic analysis of follicular dendritic cell sarcoma by molecular inversion probe array reveals tumor suppressor-driven biology. Mod. Pathol. 2017; 30; 1321-1334.
Massoth LR, Hung YP, Ferry JA et al. Histiocytic and dendritic cell sarcomas of hematopoietic origin share targetable genomic alterations distinct from follicular dendritic cell sarcoma. Oncologist 2021; 26; e1263-e1272.
Chen W, Lau SK, Fong D et al. High frequency of clonal immunoglobulin receptor gene rearrangements in sporadic histiocytic/dendritic cell sarcomas. Am. J. Surg. Pathol. 2009; 33; 863-873.
Go H, Jeon YK, Huh J et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology 2014; 65; 261-272.
Laginestra MA, Tripodo C, Agostinelli C et al. Distinctive histogenesis and immunological microenvironment based on transcriptional profiles of follicular dendritic cell sarcomas. Mol. Cancer Res. 2017; 15; 541-552.
Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. Cancer 1982; 50; 970-981.
Deyrup AT, Tighiouart M, Montag AG, Weiss SW. Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases. Am. J. Surg. Pathol. 2008; 32; 924-927.
Lau K, Massad M, Pollak C et al. Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. Chest 2011; 140; 1312-1318.
Lin BT, Colby T, Gown AM et al. Malignant vascular tumors of the serous membranes mimicking mesothelioma. A report of 14 cases. Am. J. Surg. Pathol. 1996; 20; 1431-1439.
Crotty EJ, McAdams HP, Erasmus JJ et al. Epithelioid hemangioendothelioma of the pleura: clinical and radiologic features. AJR Am. J. Roentgenol. 2000; 175; 1545-1549.
Zhang PJ, Livolsi VA, Brooks JJ. Malignant epithelioid vascular tumors of the pleura: report of a series and literature review. Hum. Pathol. 2000; 31; 29-34.
Mentzel T, Beham A, Calonje E, Katenkamp D, Fletcher CDM. Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases. Am. J. Surg. Pathol. 1997; 21; 363-374.
Anderson T, Zhang L, Hameed M, Rusch V, Travis WD, Antonescu CR. Thoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions. Am. J. Surg. Pathol. 2015; 39; 132-139.
Shibayama T, Makise N, Motoi T et al. Clinicopathologic characterization of epithelioid hemangioendothelioma in a series of 62 cases: a proposal of risk stratification and identification of a synaptophysin-positive aggressive subset. Am. J. Surg. Pathol. 2021; 45; 616-626.
Shibuya R, Matsuyama A, Shiba E, Harada H, Yabuki K, Hisaoka M. CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma. Histopathology 2015; 67; 827-835.
Doyle LA, Fletcher CD, Hornick JL. Nuclear expression of CAMTA1 distinguishes epithelioid hemangioendothelioma from histologic mimics. Am. J. Surg. Pathol. 2016; 40; 94-102.
Antonescu CR, Le Loarer F, Mosquera JM et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 2013; 52; 775-784.
Sharain RF, Gown AM, Greipp PT, Folpe AL. Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study. Hum. Pathol. 2019; 87; 65-74.
Anderson WJ, Fletcher CDM, Hornick JL. Loss of expression of YAP1 C-terminus as an ancillary marker for epithelioid hemangioendothelioma variant with YAP1-TFE3 fusion and other YAP1-related vascular neoplasms. Mod. Pathol. 2021; 34; 2036-2042.
Mendlick MR, Nelson M, Pickering D et al. Translocation t(1;3)(p36.3;q25) is a nonrandom aberration in epithelioid hemangioendothelioma. Am. J. Surg. Pathol. 2001; 25; 684-687.
Tanas MR, Sboner A, Oliveira AM et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci. Transl. Med. 2011; 3; 98ra82.
Errani C, Zhang L, Sung YS et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 2011; 50; 644-653.
Patel NR, Salim AA, Sayeed H et al. Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1-CAMTA1 fusion variants. Histopathology 2015; 67; 699-708.
Dermawan JK, Azzato EM, Billings SD et al. YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases. Mod. Pathol. 2021; 34; 2211-2221.
Rosenbaum E, Jadeja B, Xu B et al. Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Mod. Pathol. 2020; 33; 591-602.
Suurmeijer AJH, Dickson BC, Swanson D, Sung YS, Zhang L, Antonescu CR. Variant WWTR1 gene fusions in epithelioid hemangioendothelioma-a genetic subset associated with cardiac involvement. Genes Chromosomes Cancer 2020; 59; 389-395.
Seavey CN, Hallett A, Li S et al. Loss of CDKN2A cooperates with WWTR1(TAZ)-CAMTA1 gene fusion to promote tumor progression in epithelioid hemangioendothelioma. Clin. Cancer Res. 2023; 29; 2480-2493.
Gerald WL, Miller HK, Battifora H, Miettinen M, Silva EG, Rosai J. Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals. Am. J. Surg. Pathol. 1991; 15; 499-513.
Gerald WL, Ladanyi M, de Alava E et al. Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants. J. Clin. Oncol. 1998; 16; 3028-3036.
Al-Ibraheemi A, Broehm C, Tanas MR et al. Desmoplastic small round cell tumors with atypical presentations: a report of 34 cases. Int. J. Surg. Pathol. 2019; 27; 236-243.
Parkash V, Gerald WL, Parma A, Miettinen M, Rosai J. Desmoplastic small round cell tumor of the pleura. Am. J. Surg. Pathol. 1995; 19; 659-665.
Karavitakis EM, Moschovi M, Stefanaki K et al. Desmoplastic small round cell tumor of the pleura. Pediatr. Blood Cancer 2007; 49; 335-338.
Ouarssani A, Atoini F, Ait Lhou F, Rguibi Idrissi M. Desmoplastic small round cell tumor of the pleura. Thorac. Cancer 2011; 2; 117-119.
Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B et al. Multimodality treatment of desmoplastic small round cell tumor: chemotherapy and complete cytoreductive surgery improve patient survival. Clin. Cancer Res. 2018; 24; 4865-4873.
Lae ME, Roche PC, Jin L, Lloyd RV, Nascimento AG. Desmoplastic small round cell tumor: a clinicopathologic, immunohistochemical, and molecular study of 32 tumors. Am. J. Surg. Pathol. 2002; 26; 823-835.
Zhang PJ, Goldblum JR, Pawel BR, Fisher C, Pasha TL, Barr FG. Immunophenotype of desmoplastic small round cell tumors as detected in cases with EWS-WT1 gene fusion product. Mod. Pathol. 2003; 16; 229-235.
de Alava E, Ladanyi M, Rosai J, Gerald WL. Detection of chimeric transcripts in desmoplastic small round cell tumor and related developmental tumors by reverse transcriptase polymerase chain reaction. A specific diagnostic assay. Am. J. Pathol. 1995; 147; 1584-1591.
Lee SB, Kolquist KA, Nichols K et al. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nat. Genet. 1997; 17; 309-313.
Alaggio R, Rosolen A, Sartori F et al. Spindle cell tumor with EWS-WT1 transcript and a favorable clinical course: a variant of DSCT, a variant of leiomyosarcoma, or a new entity? Report of 2 pediatric cases. Am. J. Surg. Pathol. 2007; 31; 454-459.
Ud Din N, Pekmezci M, Javed G et al. Low-grade small round cell tumor of the cauda equina with EWSR1-WT1 fusion and indolent clinical course. Hum. Pathol. 2015; 46; 153-158.
Schoolmeester JK, Folpe AL, Nair AA et al. EWSR1-WT1 gene fusions in neoplasms other than desmoplastic small round cell tumor: a report of three unusual tumors involving the female genital tract and review of the literature. Mod. Pathol. 2021; 34; 1912-1920.
Charles AK, Moore IE, Berry PJ. Immunohistochemical detection of the Wilms' tumour gene WT1 in desmoplastic small round cell tumour. Histopathology 1997; 30; 312-314.
Hill DA, Pfeifer JD, Marley EF et al. WT1 staining reliably differentiates desmoplastic small round cell tumor from Ewing sarcoma/primitive neuroectodermal tumor. An immunohistochemical and molecular diagnostic study. Am. J. Clin. Pathol. 2000; 114; 345-353.
Barnoud R, Sabourin JC, Pasquier D et al. Immunohistochemical expression of WT1 by desmoplastic small round cell tumor: a comparative study with other small round cell tumors. Am. J. Surg. Pathol. 2000; 24; 830-836.
Arnold MA, Schoenfield L, Limketkai BN, Arnold CA. Diagnostic pitfalls of differentiating desmoplastic small round cell tumor (DSRCT) from Wilms tumor (WT): overlapping morphologic and immunohistochemical features. Am. J. Surg. Pathol. 2014; 38; 1220-1226.
Wong YP, Buckley K, Iwenofu OH et al. Selective immunoreactivity for WT1 carboxy-terminus distinguishes desmoplastic small round cell tumor from its histologic mimics. Pediatr. Dev. Pathol. 2022; 25; 504-510.
Bulbul A, Shen JP, Xiu J et al. Genomic and proteomic alterations in desmoplastic small round blue-cell tumors. JCO Precis Oncol 2018; 2; 1-9.
Lamhamedi-Cherradi SE, Maitituoheti M, Menegaz BA et al. The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. Nat. Commun. 2022; 13; 3057.